|Articles|December 28, 2021

The Unutterable Rage

Poetry approaches the visceral experience of intense emotion better than prose or medical reports.

POETRY

Dr Doherty is a retired clinical and academic child and family psychiatrist.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe

Related Content

The Night We Heard Ella Sing

ByRichard M. Berlin, MD

August 13th 2026

Presenting Our August 2026 Theme: Suicide

ByLeah Kuntz

August 5th 2026

Requiring AI-Driven Suicide Risk Stratification in Emergency Settings: Helpful or Risky?

BySarah Cheema, MD,Andrew Canto, MD,Nicolas Badre, MD

July 21st 2026

Signal in Noise: How Can Artificial Intelligence Benefit Psychiatric Practice?

ByJoseph F. Goldberg, MD,Roy Perlis, MD

June 30th 2026

Assessment of Suicide Risk in Individuals With Schizophrenia

ByCarla Kotzé, PhD, MMed, MPhil, FCPsych,Johannes Lodewikus Roos, MD, DSc, MMed, FCPsych

June 17th 2026

Latest CME

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

Register now!

Video

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

The Unutterable Rage

Related Content

The Night We Heard Ella Sing

Presenting Our August 2026 Theme: Suicide

Requiring AI-Driven Suicide Risk Stratification in Emergency Settings: Helpful or Risky?

Signal in Noise: How Can Artificial Intelligence Benefit Psychiatric Practice?

Assessment of Suicide Risk in Individuals With Schizophrenia

Latest CME

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Jersey City Psychiatry

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Trending on Psychiatric Times

FDA Clears First and Only Single-Biomarker Blood Test for Alzheimer Disease Assessment

Patent Application Published: MDMA-N-Acylethanolamines for the Treatment of PTSD, Anxiety, and Eating Disorders

Kratom Component in Clinical Trial for Opioid Use Disorder

Migraine and Psychiatric Comorbidities

NIDA Awards PleoPharma $6.5 Million Grant to Advance Phase 3 Trial of PP-01 for Cannabis Use Disorder